<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1289">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05457998</url>
  </required_header>
  <id_info>
    <org_study_id>1745146</org_study_id>
    <nct_id>NCT05457998</nct_id>
  </id_info>
  <brief_title>BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers</brief_title>
  <official_title>BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Warren Alpert Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Butler Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study aims to examine biomarkers of Alzheimer's disease as early as possible&#xD;
      which could potentially be a screening tool for the general population. This observational&#xD;
      study will take place at the Memory and Aging Program at Butler Hospital. The study will&#xD;
      enroll up to 200 cognitively healthy subjects aged 50 to 80 years with ongoing recruitment&#xD;
      and enrollment for 2 years and participant participation lasting approximately 5 years.&#xD;
      Disclosure of AD risk assessments will be an optional procedure. Two PET imaging sub-studies&#xD;
      will also be optional.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 7, 2022</start_date>
  <completion_date type="Anticipated">November 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in plasma biomarkers</measure>
    <time_frame>Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.</time_frame>
    <description>Validate and assess longitudinal changes from baseline in plasma amyloid, phosphorylated tau (p-tau) and other fluid biomarkers (e.g., neurofilament light).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change in cerebral amyloid pathology</measure>
    <time_frame>Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 5 years after baseline.</time_frame>
    <description>Longitudinal assessment of cerebral amyloidosis based on amyloid PET imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change in Tau PET measures</measure>
    <time_frame>Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.</time_frame>
    <description>Longitudinal assessment of cerebral tau accumulation based on tau PET imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of cognitive decline as measured by traditional cognitive and behavioral assessments</measure>
    <time_frame>Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cognitive decline as measured by digital cognitive assessments</measure>
    <time_frame>Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in retinal imaging metrics</measure>
    <time_frame>Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in psychological wellness as measured by the Geriatric Depression Scale</measure>
    <time_frame>Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Main study population: Cognitively unimpaired individuals (50-80 y)</arm_group_label>
    <description>This study will be conducted in up to 200 subjects between the ages of 50-80 who are cognitively unimpaired with ongoing recruitment and enrollment for 2 years and participant follow-up for 5 years.&#xD;
Following analysis of blood plasma at screening, all p-tau 217 plasma positive participants will be enrolled and scheduled for the baseline visit. A randomly selected 1/10 of all p-tau 217 plasma negative participants will also be enrolled. We will enroll participants until we have reached a sample size where 3/4 of participants are amyloid positive.&#xD;
FOLLOW-UP FOR 5 YEARS: Cognitive testing, blood draws and retinal imaging will be conducted at baseline and 12 months. Cognitive testing and blood draws will be conducted at 24 months and 36 months.&#xD;
MRI and Amyloid PET scans will be performed at baseline and 24 months. An additional amyloid PET scan will be performed at 48 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-group 1: Optional Tau PET imaging sub-study</arm_group_label>
    <description>An optional tau PET imaging sub-study will be conducted in 70 subjects from the main study population who elect to participate.&#xD;
If enrolled in the optional tau PET imaging sub-study, participants will have three tau PET scans with [18F]RO-948: at baseline, 24 months, and 48 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-group 2: Optional Tau PET tracer comparison sub-study</arm_group_label>
    <description>An optional tau PET tracer comparison sub-study will be conducted in 30 subjects from the main study population who elect to participate. These individuals will be amyloid positive as determined by Flutemetamol amyloid PET scan.&#xD;
Tau PET scans with 3 tracers ([18F]RO-948, [18F]MK-6240, and [18F]GTP-1) will be performed at baseline and 24 months. An additional Tau PET scan with [18F]RO-948 will be performed at 48 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flutemetamol F18 Injection</intervention_name>
    <description>PET imaging of Abeta amyloid</description>
    <arm_group_label>Main study population: Cognitively unimpaired individuals (50-80 y)</arm_group_label>
    <other_name>Vizamyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[18F]-RO6958948 Injection</intervention_name>
    <description>PET imaging of Tau aggregates</description>
    <arm_group_label>Sub-group 1: Optional Tau PET imaging sub-study</arm_group_label>
    <arm_group_label>Sub-group 2: Optional Tau PET tracer comparison sub-study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[18F]-MK-6240 Injection</intervention_name>
    <description>PET imaging of Tau aggregates</description>
    <arm_group_label>Sub-group 2: Optional Tau PET tracer comparison sub-study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[18F]-GTP-1 Injection</intervention_name>
    <description>PET imaging of Tau aggregates</description>
    <arm_group_label>Sub-group 2: Optional Tau PET tracer comparison sub-study</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum and plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be conducted in up to 200 subjects between the ages of 50-80 who are&#xD;
        cognitively unimpaired. Participants must also pass all inclusion/exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals between the ages of 50 and 80 years old (inclusive)&#xD;
&#xD;
          -  Score of 12 or above on the MoCA telephone&#xD;
&#xD;
          -  Score of 27 or greater on the MMSE for individuals aged 50 to 64 years old or a score&#xD;
             of 26 or greater for individuals aged 65 to 80 years old&#xD;
&#xD;
          -  Participants in the 50-60 age range will additionally need to meet at least one of the&#xD;
             following: (1) First degree family history of dementia with onset before age 75; (2)&#xD;
             APOE e4 allele carrier; or (3) Prior elevated result on amyloid PET or amyloid CSF&#xD;
             testing&#xD;
&#xD;
          -  Conversationally fluent in English to the extent that an interpreter is not necessary&#xD;
             for comprehension of the study information, procedures, and cognitive tests.&#xD;
&#xD;
          -  If participants elect to participate in the optional disclosure procedure, they will&#xD;
             be required to have an appropriate study partner who agrees to participate in the&#xD;
             study and who is intellectually, visually, and auditory capable, and conversationally&#xD;
             fluent in English to the extent that an interpreter is not necessary.&#xD;
&#xD;
          -  Adequate visual and auditory acuity to allow neuropsychological testing.&#xD;
&#xD;
          -  Participants must be willing and able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of mild cognitive impairment or dementia&#xD;
&#xD;
          -  History of significant brain injury or other known neurologic disease or insult,&#xD;
             resulting in lasting cognitive sequelae that would confound the assessment and staging&#xD;
             of potential neurodegenerative disease (e.g., Huntington's disease, Parkinson's&#xD;
             disease, Parkinsonism due to multiple system atrophy (MSA), progressive supranuclear&#xD;
             palsy (PSP), Shy Drager Syndrome (SDS) or other neuro-degenerative dementias,&#xD;
             encephalitis or other brain infection, epilepsy or stroke with lasting impairment to&#xD;
             cognitive function).&#xD;
&#xD;
          -  Current serious or unstable systemic illness or organ failure that, in the PI's&#xD;
             judgement, would make it difficult to participate in the study (e.g., such as terminal&#xD;
             cancer, cardiovascular, hepatic, renal, gastroenterological, respiratory,&#xD;
             endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other&#xD;
             conditions ). History of cancer is acceptable with at least one year in remission with&#xD;
             a good prognosis.&#xD;
&#xD;
          -  Individuals with clinically significant depression, bipolar disorder, anxiety, or&#xD;
             suicidal ideations within the past year as defined by the most current version of the&#xD;
             Diagnostic and Statistical Manual of Mental Disorders (DSM).&#xD;
&#xD;
          -  A history of schizophrenia as defined by the most current version of the DSM.&#xD;
&#xD;
          -  History within the past year of chronic alcohol or drug abuse/dependence as defined by&#xD;
             the most current version of the DSM.&#xD;
&#xD;
          -  Marijuana use is acceptable, but frequent users will be asked to abstain from use&#xD;
             within 24 hours of any assessments.&#xD;
&#xD;
          -  Refusing or unable to complete any study procedures.&#xD;
&#xD;
          -  Currently enrolled in another study which involves clinical drug trial or other&#xD;
             medical intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Salloway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butler Hospital Memory and Aging Program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara Tang, BA</last_name>
    <phone>401-455-6402</phone>
    <email>memory@butler.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philip Caffery, PhD</last_name>
    <phone>401-455-6200</phone>
    <phone_ext>21004</phone_ext>
    <email>pcaffery@butler.org</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>July 11, 2022</study_first_submitted>
  <study_first_submitted_qc>July 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2022</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Butler Hospital</investigator_affiliation>
    <investigator_full_name>Stephen Salloway</investigator_full_name>
    <investigator_title>Martin M. Zucker Professor of Psychiatry and Human Behavior; Professor of Neurology, Alpert Medical School of Brown University; Associate Director, Brown Center for Alzheimer's Disease Research</investigator_title>
  </responsible_party>
  <keyword>Early diagnosis</keyword>
  <keyword>Biomarker</keyword>
  <keyword>PET</keyword>
  <keyword>MRI</keyword>
  <keyword>Î²-amyloid</keyword>
  <keyword>tau</keyword>
  <keyword>Cognitive test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flutemetamol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

